已核实 DOI PubMed 相关产品: 22

Combining immune checkpoint blockade with ATP-based immunogenic cell death amplifier for cancer chemo-immunotherapy

Journal 2022 · IF 14.903 · 发表于 2022 年 5 月 16 日
作者: Jiulong Zhang,Xiaoyan Sun,Xiufeng Zhao,Chunrong Yang,Menghao Shi,Benzhuo Zhang,Haiyang Hu,Mingxi Qiao,Dawei Chen,Xiuli Zhao
阅读全文 在 PubMed 查看

摘要

Amplifying “eat me signal” during tumor immunogenic cell death (ICD) cascade is crucial for tumor immunotherapy. Inspired by the indispensable role of adenosine triphosphate (ATP, a necessary “eat me signal” for ICD), a versatile ICD amplifier was developed for chemotherapy-sensitized immunotherapy. Doxorubicin (DOX), ATP and ferrous ions (Fe 2+ ) were co-assembled into nanosized amplifier (ADO-Fe) through π‒π stacking and coordination effect. Meanwhile, phenylboric acid-polyethylene glycol-phenylboric acid (PBA-PEG-PBA) was modified on the surface of ADO-Fe (denoted as PADO-Fe) by the virtue of d -ribose unit of ATP. PADO-Fe could display active targetability against tumor cells via sialic acid/PBA interaction. In acidic microenvironment, PBA-PEG-PBA would dissociate from amplifier. Moreover, high H 2 O 2 concentration would induce hydroxyl radical (·OH) and oxygen (O 2 ) generation through Fenton reaction by Fe 2+ . DOX and ATP would be released from the amplifier, which could induce ICD effect and “ICD adjuvant” to amplify this process. Together with programmed death ligands 1 (PD-L1) checkpoint blockade immunotherapy, PADO-Fe could not only activate immune response against primary tumor, but also strong abscopal effect against distant tumor. Our simple and multifunctional ICD amplifier opens a new window for enhancing ICD effect and immune checkpoint blockade therapy.

本研究中使用的阿拉丁产品

22 款产品在本文中被引用